BIOCELL TECHNOLOGY RECEIVES FROST & SULLIVAN BEST PRACTICES IN CUSTOMER VALUE ENHANCEMENT OF THE YEAR AWARD

The Prestigious Award Recognizes BioCell Technology’s Exemplary Best Practices and Strategies in the Business and Science of BioCell Collagen II®

Newport Beach, CA – February 16, 2011 – BioCell Technology LLC received Frost & Sullivan’s 2010 North American Customer Value Enhancement of the Year Award in Bone and Joint Health Ingredients. The Frost & Sullivan Award is presented annually to a company that has demonstrated excellence in implementing strategies that proactively create value through research and development activities, with a focus on improving the return on the investment that customers make in its products.

BioCell Technology is acknowledged by Frost & Sullivan, a global market consulting and research firm, for its research excellence and inordinate focus on creating value beyond simply superior customer service. Frost & Sullivan employed its unique research philosophy called TEAM Research methodology, founded upon the CEO’s 360 Degree Perspective, to recognize outstanding achievements in BioCell Technology’s diligence and innovation of BioCell Collagen II®, an essential healthy aging ingredient promoting both joint and skin health.

"BioCell Technology has proven consistently to be a significant contender in a market that has been dominated by glucosamine/chondroitin products," said Suhail Ishaq, Vice President of BioCell Technology. "In light of the recent negative research publications questioning their efficacy, consumers are looking for more effective options that deliver more reliable results. BioCell Collagen II has unique differentiated properties and is supported by substantial clinical data that conclusively prove the effectiveness of the product for joint health. In my opinion, no other ingredient is able to demonstrate such consistent and clinically-relevant data. We appreciate Frost & Sullivan’s recognition of our efforts to deliver solution driven values to our customers and we are deeply honored to have received this award. "

Frost & Sullivan’s Best Practices research praised BioCell Technology and its executives for their world-class performances to become one of best-in-class companies in managing phenomenal growth, technological innovation and strong leadership. In particular, its patented process and scientific substantiation of BioCell Collagen II®, created for the safety and efficacy in joint health conditions through in vivo studies and human clinical trials, is identified as a key factor that helps differentiate the dietary ingredient from other alternatives. Additionally, BioCell Collagen II® is positioned as a next-generation ingredient due to its multi-layered support of various joint symptoms in concomitance with potential regenerative capability of degraded cartilage. While constant updates of knowledge and clinical information on BioCell Collagen II® increase the awareness and confidence of consumers, its comprehensive intellectual property portfolio ensures that BioCell Technology protects their core competencies from predatory influences. The analysis, based on the Best Practices research, also demonstrated that the company has improved strategies and processes, through their exemplary practices in various functional disciplines enhancing customer value and and driving outstanding corporate growth in the highly competitive market.

“Significant competition in the market for collagen peptides means that manufacturers have to distinguish themselves with optimum technical and business support to become market leaders,” said Dr. Kaushik Ramakrishnan, Senior Research Analyst at Frost & Sullivan. “BioCell Technology has the right combination of supporting clinical data and a co-branding strategy. This is augmented by their strong IP protection, which ensures a long term and delightful relationship with clients and consumers.”

The prestigious Best Practices award is recognized worldwide by the media, the investment community and end-user markets. Recently, BioCell Technology announced positive top-line results for BioCell Collagen II®’s joint health improvement clinical study and affirmation of GRAS (Generally Regarded As Safe) status, which expands its application into functional foods.

To learn how to obtain a copy of the Frost & Sullivan Best Practices Research analysis report on BioCell Technology, please contact the company at (714) 632-1231.

About BioCell Collagen II:

BioCell Collagen II® is a novel dietary ingredient marketed as a healthy aging nutritional supplement that promotes both healthy joints and youthful-looking skin. It is unique in that it is a naturally-occurring matrix whose three major constituents: collagen type II, chondroitin sulfate and hyaluronic acid, are reduced to highly-bioavailable, very low molecular weight forms due to its patented hydrolysis process. Made from articular cartilage, its composition is similar to that of human articular joint cartilage.

About BioCell Technology:

Founded in 1997, BioCell Technology, LLC is the exclusive supplier of BioCell Collagen II®. BioCell Technology, LLC owns the exclusive rights to market BioCell Collagen II® under the United States Patents. BioCell Collagen II® is a branded registered logo that is available for display on its client’s labels to market under their own brand name or formulas. For more information on BioCell Collagen II®, please contact BioCell Technology, LLC at (714) 632-1231, or visit them at www.biocelltechnology.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more tha